New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.

ABSTRACT: Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound to a potent cytotoxic agent (the payload), via a linker, contributing to an improved therapeutic index. Currently, three ADCs received approval by the US Food and Drug Administration (FDA) and are in routine clinical use in different treatment settings; many more ADCs are in earlier and later stages of development, and their future approval will improve treatment options for patients with advanced but potentially also early-stage BC over time. Just recently, the results of three phase 3 trials (

SUBMITTER: Koster KL 

PROVIDER: S-EPMC9400777 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature